#USA #Cranford #LYMPHIR #Citius Oncology #Pembrolizumab

Citius Oncology's Promising Findings in Gynecologic Cancer Therapy

Citius Oncology, Inc., a biopharmaceutical company focusing on oncology treatments, recently announced positive topline results from a Phase 1 clinical trial investigating the efficacy of their drug, LYMPHIR™, in combination with pembrolizumab (KEYTRUDA®). Conducted by investigators from the University of Pittsburgh, this clinical study evaluated the effects of this combination therapy on patients suffering from relapsed or refractory gynecologic cancers, specifically ovarian and endometrial malignancies.

Overview of the Clinical Trial

The Phase 1 study was designed as an open-label, dose-escalation investigation to assess the safety and preliminary efficacy of LYMPHIR in a population deemed heavily pretreated. Among the 25 evaluable patients, the trial sought to establish an optimal dosage of LYMPHIR when combined with pembrolizumab. The objective was not only to check for unexpected safety issues but also to gauge the potential enhancement of anti-tumor activity.

The results from this investigator-initiated study revealed no significant unexpected safety signals, indicating that the patients tolerated the treatment well, with no serious immune-related adverse events reported at any dosage level. Dr. Myron Czuczman, Citius Oncology’s Executive Vice President and Chief Medical Officer, expressed optimism regarding the safety profile and sustained disease control observed in the participants. He emphasized that the evidence suggests a heightened anti-tumor response when LYMPHIR is paired with KEYTRUDA, making it a promising avenue for further investigation in Phase 2 studies.

Efficacy Results

Among the 21 evaluable patients, a 24% objective response rate (ORR) was documented along with a 48% clinical benefit rate (CBR), which includes complete responses, partial responses, or stable disease lasting six months or more. Full results, including safety and clinical efficacy data, are set to be presented at an upcoming international cancer conference later this year, which could further validate the importance of these findings.

Dr. Alexander Olawaiye, the principal investigator, remarked on the excitement surrounding the efficacy signal observed through this combination therapy, especially in the context of the limited impact that current immuno-oncology strategies have produced in treating ovarian cancer up to this point. If subsequent studies reaffirm these initial results, LYMPHIR in combination with pembrolizumab could revolutionize treatment protocols for this challenging patient population.

Significance of Gynecologic Cancers

Recurrent and metastatic gynecologic cancers, specifically ovarian and endometrial cancers, remain among the most prevalent malignancies in the U.S., often diagnosed at advanced stages. Current statistics estimate 70,000 new endometrial cancer cases annually, while ovarian cancer results in about 12,700 deaths. Traditional treatments such as platinum-based chemotherapy have shown efficacy initially; however, most patients eventually experience relapse with limited responses to therapies such as PD-1 inhibitors, demonstrating a critical unmet need for novel therapeutic approaches.

Through its designed mechanism, LYMPHIR targets specific receptor abnormalities, potentially enhancing immune responses by transiently depleting regulatory T-cells. The results from this trial are expected to bring renewed hope for the many patients facing these difficult-to-treat malignancies.

About LYMPHIR™

LYMPHIR, which is a recombinant fusion protein that combines the interleukin-2 receptor binding domain with diphtheria toxin fragments, was previously approved for use in relapsed or refractory cutaneous T-cell lymphoma (CTCL). While this current study is exploring LYMPHIR’s potential beyond its FDA-approved indications, the findings could pave the way for its broader application in treating other types of malignancies.

This innovative treatment strategy has the potential to synergize the existing capabilities of pembrolizumab, leading to a new frontier in combating immune resistance often seen in cancer therapies.

Citius Oncology continues to advance its mission to develop targeted therapies that fulfill unmet needs in oncology, demonstrating their commitment to enhancing patient outcomes through rigorous research and clinical trials. The outcomes from this trial not only represent a significant step for Citius Oncology but also for patients battling ovarian and endometrial cancers.

For more details about the company and its innovative therapies, you can visit Citius Oncology’s website.